Cardiovascular Therapy Articles & Analysis
9 news found
BOC Sciences' monthly report released in August showed that its peptide products had vastly facilitated the R&D of cardiovascular therapies. February is set as American Heart Month since heart disease is the number one cause of death for most groups, affecting all ages, genders, and races. ...
Mitochondrial DNA (mtDNA) plays an important role in the pathogenesis of the cardiovascular disease (CVD), especially in heart failure and ischemic heart disease. ...
” About the CardiAMP Cell Therapy Program CardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter ...
(Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. ...
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that it has entered into a long-term lease for a new facility in Sunnyvale, California. ...
[Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ischemia with refractory angina. ...
The simulation is intended to boost physician confidence, reduce operating times, and decrease the risk of complications. Cardiovascular transcatheter therapies have transformed the treatment landscape, expanding options for patients with structural heart disease. ...
ByBIOMODEX
V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced the appointment of Bill Hughes as its Chief Financial Officer (CFO) today. ...
Despite improvements in dialysis therapy, cardiovascular disease remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of that for the general population. ...